Ignite Creation Date:
2024-05-06 @ 5:59 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05501886
Status:
RECRUITING
Last Update Posted:
2023-08-01
First Post:
2022-08-12
Brief Title:
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HRHER2- Breast Cancer VIKTORIA-1
Sponsor:
Celcuity Inc
Organization:
Celcuity Inc
Organization Data
Organization:
Celcuity Inc
Class:
INDUSTRY
Study ID:
CELC-G-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Celcuity Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None